JP2009504772A5 - - Google Patents

Download PDF

Info

Publication number
JP2009504772A5
JP2009504772A5 JP2008527150A JP2008527150A JP2009504772A5 JP 2009504772 A5 JP2009504772 A5 JP 2009504772A5 JP 2008527150 A JP2008527150 A JP 2008527150A JP 2008527150 A JP2008527150 A JP 2008527150A JP 2009504772 A5 JP2009504772 A5 JP 2009504772A5
Authority
JP
Japan
Prior art keywords
optionally substituted
sch
och
substituted
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008527150A
Other languages
English (en)
Japanese (ja)
Other versions
JP5118039B2 (ja
JP2009504772A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/032199 external-priority patent/WO2007094819A2/en
Publication of JP2009504772A publication Critical patent/JP2009504772A/ja
Publication of JP2009504772A5 publication Critical patent/JP2009504772A5/ja
Application granted granted Critical
Publication of JP5118039B2 publication Critical patent/JP5118039B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008527150A 2005-08-18 2006-08-17 Ｈｓｐ９０活性を調節するトリアゾール化合物 Expired - Fee Related JP5118039B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US70931005P 2005-08-18 2005-08-18
US60/709,310 2005-08-18
US72410505P 2005-10-06 2005-10-06
US60/724,105 2005-10-06
PCT/US2006/032199 WO2007094819A2 (en) 2005-08-18 2006-08-17 Triazole compounds that modulate hsp90 activity

Publications (3)

Publication Number Publication Date
JP2009504772A JP2009504772A (ja) 2009-02-05
JP2009504772A5 true JP2009504772A5 (https=) 2009-10-01
JP5118039B2 JP5118039B2 (ja) 2013-01-16

Family

ID=38371934

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008527150A Expired - Fee Related JP5118039B2 (ja) 2005-08-18 2006-08-17 Ｈｓｐ９０活性を調節するトリアゾール化合物

Country Status (7)

Country Link
US (1) US7662813B2 (https=)
EP (1) EP1928846B1 (https=)
JP (1) JP5118039B2 (https=)
AU (1) AU2006338265B2 (https=)
CA (1) CA2618628C (https=)
TW (1) TWI446910B (https=)
WO (1) WO2007094819A2 (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006055760A1 (en) * 2004-11-18 2006-05-26 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
US8399464B2 (en) * 2005-03-09 2013-03-19 Nippon Kayaku Kabushiki Kaisha HSP90 inhibitor
JP5178515B2 (ja) 2005-08-12 2013-04-10 シンタ ファーマシューティカルズ コーポレーション Ｈｓｐ９０活性を調節するピラゾール化合物
WO2007094819A2 (en) * 2005-08-18 2007-08-23 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
US20070250391A1 (en) * 2006-04-05 2007-10-25 Prade Hendrik D Merchandising system and method for food and non-food items for a meal kit
DE102006023337A1 (de) * 2006-05-18 2007-11-22 Merck Patent Gmbh Triazolderivate II
EP2035396B1 (en) 2006-05-25 2014-05-14 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
WO2007139960A2 (en) * 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Compounds that modulate hsp90 activity and methods for identifying same
US8183384B2 (en) * 2006-05-25 2012-05-22 Synta Pharmaceuticals Corp. Triazole compounds that modulate HSP90 activity
TW200806637A (en) * 2006-05-25 2008-02-01 Synta Pharmaceuticals Corp Synthesis of triazole compounds that modulate HSP90 activity
EP2026797A2 (en) * 2006-05-25 2009-02-25 Synta Pharmaceuticals Corporation Method for treating non-hodgkin's lymphoma
CA2653222A1 (en) 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
AU2007267843B2 (en) 2006-05-25 2011-10-13 Synta Pharmaceuticals Corp. Method for treating proliferative disorders associated with protooncogene products
WO2008021364A2 (en) * 2006-08-17 2008-02-21 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
US20110046125A1 (en) * 2006-10-19 2011-02-24 Synta Pharmaceuticals Corp. Method for treating infections
WO2008057246A2 (en) * 2006-10-26 2008-05-15 Synta Pharmaceuticals Corp. Method for treating inflammatory disorders
US8299107B2 (en) * 2007-02-08 2012-10-30 Synta Pharmaceuticals Corporation Triazole compounds that modulate HSP90 activity
WO2008153730A2 (en) * 2007-05-25 2008-12-18 Synta Pharmaceuticals Corp. Method for treating proliferative disorders associated with mutations in c-met
CN101801983B (zh) 2007-08-13 2014-01-29 辛塔制药公司 调控hsp90活性的三唑化合物
US7932279B2 (en) 2007-10-12 2011-04-26 Arqule, Inc. Substituted tetrazole compounds and uses thereof
KR100947696B1 (ko) 2007-11-23 2010-03-16 재단법인서울대학교산학협력재단 1,2,4-트리아졸 유도체를 함유하는 Ｈｓｐ９０ 억제제 및이를 이용한 항암제
LT5623B (lt) 2008-04-30 2010-01-25 Biotechnologijos Institutas, , 5-aril-4-(5-pakeistieji 2,4-dihidroksifenil)-1,2,3-tiadiazolai kaip hsp90 šaperono slopikliai ir tarpiniai junginiai jiems gauti
US9156836B2 (en) * 2008-05-16 2015-10-13 Synta Pharmaceuticals Corp. Tricyclic triazole compounds that modulate HSP90 activity
WO2009148599A1 (en) 2008-06-04 2009-12-10 Synta Pharmaceuticals Corp. Pyrrole compunds that modulate hsp90 activity
US8648071B2 (en) 2008-06-27 2014-02-11 Synta Pharmaceuticals Corp. Hydrazonamide compounds that modulate Hsp90 activity
US8106083B2 (en) 2008-08-08 2012-01-31 Synta Pharmaceuticals Corp. Triazole compounds that modulate HSP90 activity
ES2415234T3 (es) * 2008-08-08 2013-07-24 Synta Pharmaceuticals Corp. Compuestos de triazol que modulan la actividad Hsp90
US9205086B2 (en) 2010-04-19 2015-12-08 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor
JP2014520808A (ja) 2011-07-07 2014-08-25 シンタ ファーマシューティカルズ コーポレーション Ｈｓｐ９０阻害化合物を用いた癌の治療
DE112012004314B4 (de) * 2011-10-14 2024-01-11 San Jamar Inc. Dispenser mit kapazitivem Näherungssensor
AU2012332424A1 (en) 2011-11-02 2014-06-05 Synta Pharmaceuticals Corp. Combination therapy of Hsp90 inhibitors with platinum-containing agents
EP2773345A1 (en) 2011-11-02 2014-09-10 Synta Pharmaceuticals Corp. Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
WO2013074594A1 (en) 2011-11-14 2013-05-23 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with braf inhibitors
CN113929866B (zh) 2013-07-08 2023-07-07 旭化成株式会社 改性的树脂和树脂组合物
WO2015066053A2 (en) * 2013-10-28 2015-05-07 Synta Pharmaceuticals Corp. Targeted therapeutics
EP3653611A1 (en) * 2018-11-15 2020-05-20 Centre National De La Recherche Scientifique Inhibitors of metallo-beta-lactamases

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB928919A (en) * 1960-08-16 1963-06-19 Bellon Labor Sa Roger Triazole derivatives and a process for their preparation
US4178253A (en) 1977-04-05 1979-12-11 Ciba-Geigy Corporation Corrosion inhibited lubricant compositions
US4269846A (en) * 1979-10-29 1981-05-26 Usv Pharmaceutical Corporation Heterocyclic compounds useful as anti-allergy agents
JPS5910574A (ja) 1982-07-07 1984-01-20 Fujisawa Pharmaceut Co Ltd トリアゾ−ル誘導体およびその製造法
FR2546887B1 (fr) 1983-05-30 1985-08-30 Paris 7 Universite Procede de preparation de dihydro-2,4 triazol-1,2,4 thiones-3 disubstituees en positions 4 et 5 et nouveaux composes pouvant etre prepares par ce procede
US4740568A (en) * 1985-04-09 1988-04-26 Minnesota Mining And Manufacturing Company Triazolinethione-containing polymer
US4624995A (en) * 1985-04-09 1986-11-25 Minnesota Mining And Manufacturing Company Triazolinethione-containing polymer
US5436252A (en) * 1986-12-19 1995-07-25 Merrell Dow Pharmaceuticals Inc. 5-aryl-3H-1,2,4-triazol-3-ones and their use in the treatment of neurodegenerative disorders
US5006650A (en) * 1987-02-11 1991-04-09 The Upjohn Company Novel N-1 substituted beta-lactams as antibiotics
DE3729070A1 (de) * 1987-09-01 1989-03-09 Bayer Ag Substituierte triazolinone
US5241074A (en) 1988-05-09 1993-08-31 Bayer Aktiengesellschaft Sulphonylaminocarbonyltriazolinones
US5219722A (en) 1990-09-21 1993-06-15 Konica Corporation Silver halide color photographic light-sensitive material
SK278998B6 (sk) * 1991-02-01 1998-05-06 Merck Sharp & Dohme Limited Deriváty imidazolu, triazolu a tetrazolu, spôsob i
JPH0510574A (ja) * 1991-06-28 1993-01-19 Toshiba Corp 空気調和機
DE69330713T2 (de) * 1992-03-13 2002-07-04 Merck Sharp & Dohme Ltd., Hoddesdon Imidazol-, triazol- und tetrazolderivate
TW218017B (https=) * 1992-04-28 1993-12-21 Takeda Pharm Industry Co Ltd
DE4222771A1 (de) * 1992-07-10 1994-01-13 Bayer Ag Heterocyclyltriazolinone
DE4234801A1 (de) 1992-10-15 1994-04-21 Bayer Ag Sulfonylaminocarbonyltriazolinone
DE4303376A1 (de) * 1993-02-05 1994-08-11 Bayer Ag Substituierte Triazolinone
DE4303676A1 (de) * 1993-02-09 1994-08-11 Bayer Ag 1-Aryltriazolin(thi)one
DE4411913A1 (de) 1994-04-07 1995-10-12 Bayer Ag Substituierte Sulfonylaminocarbonyltriazolinone
US5538988A (en) * 1994-04-26 1996-07-23 Martinez; Gregory R. Benzocycloalkylazolethione derivatives
US5489598A (en) * 1994-06-08 1996-02-06 Warner-Lambert Company Cytoprotection utilizing aryltriazol-3-thiones
JP3372365B2 (ja) * 1994-08-19 2003-02-04 富士写真フイルム株式会社 ハロゲン化銀写真感光材料およびそれを用いた画像形成方法
DE19502579A1 (de) 1995-01-27 1996-08-01 Bayer Ag Sulfonylamino(thio)carbonyl-triazolin(thi)one
US6080772A (en) 1995-06-07 2000-06-27 Sugen, Inc. Thiazole compounds and methods of modulating signal transduction
DE19521162A1 (de) * 1995-06-09 1996-12-12 Bayer Ag N-Aryl-1,2,4-triazolin-5-one
DE19525162A1 (de) 1995-07-11 1997-01-16 Bayer Ag Sulfonylamino(thio)carbonylverbindungen
AU6517196A (en) 1995-07-13 1997-02-10 Knoll Aktiengesellschaft Piperazine derivatives as therapeutic agents
DE19540737A1 (de) 1995-11-02 1997-05-07 Bayer Ag Substituierte Sulfonylamino(thio)carbonylverbindungen
DE19609059A1 (de) 1996-03-08 1997-09-11 Bayer Ag Substituierte Arylsulfonylamino(thio)carbonyl-triazolin(thi)one
ZA974703B (en) 1996-05-30 1997-12-30 Bayer Ag Substituted sulfonylamino(thio)carbonyl compounds.
TW467902B (en) * 1996-07-31 2001-12-11 Bristol Myers Squibb Co Diphenyl heterocycles as potassium channel modulators
DE19632945A1 (de) 1996-08-16 1998-02-19 Bayer Ag Substituierte Sulfonylamino(thio)carbonylverbindungen
JP2001504121A (ja) * 1996-11-12 2001-03-27 セプラコール，インク． ２ｒ，４ｓ，ｒ，ｓ―および２ｓ，４ｒ，ｒ，ｓ―ヒドロキシイトラコナゾール―およびヒドロキシサパーコナゾール誘導体
US5968921A (en) 1997-10-24 1999-10-19 Orgegon Health Sciences University Compositions and methods for promoting nerve regeneration
JP3788676B2 (ja) * 1997-11-11 2006-06-21 富士写真フイルム株式会社 有機エレクトロルミネツセンス素子材料およびそれを使用した有機エレクトロルミネツセンス素子
US6583090B1 (en) * 1998-03-09 2003-06-24 Basf Aktiengesellschaft Hetaryl-substituted benzyl phenyl ethers, method for the production thereof, and their use for combating harmful fungi and animal pests
TWI274750B (en) 1999-01-12 2007-03-01 Abbott Gmbh & Co Kg Triazole compounds showing high affinity to dopamine D3 receptor and pharmaceutical composition comprising the same
JP2000284412A (ja) 1999-03-30 2000-10-13 Fuji Photo Film Co Ltd 熱現像写真材料
US6492406B1 (en) * 1999-05-21 2002-12-10 Astrazeneca Ab Pharmaceutically active compounds
US20040110684A1 (en) 1999-08-02 2004-06-10 Universite Catholique De Louvain Novel pharmaceutical compositions for modulating angiogenesis
WO2001072779A1 (en) 2000-03-24 2001-10-04 Duke University Characterization of grp94-ligand interactions and purification, screening, and therapeutic methods relating thereto
US20030216385A1 (en) 2000-05-19 2003-11-20 Takahiko Tobe Triazole derivatives
AU2001271567A1 (en) 2000-06-29 2002-01-14 Trustees Of Boston University Use of geldanamycin and related compounds for prophylaxis or treatment of fibrogenic disorders
AU2001292548B2 (en) 2000-07-28 2005-06-16 Sloan-Kettering Institute For Cancer Research Methods for treating cell proliferative disorders and viral infections
CA2426762A1 (en) 2000-11-02 2002-05-10 Sloan-Kettering Institute For Cancer Research Methods for enhancing the efficacy of cytotoxic agents through the use of hsp90 inhibitors
DE10109866A1 (de) 2001-03-01 2002-09-05 Abbott Gmbh & Co Kg Triazolverbindungen und deren Verwendung zur Prophylaxe und Therapie neurodegenerativer Erkrankungen, Hirntrauma und zerebraler Ischämie
AU2002252179A1 (en) 2001-03-01 2002-09-19 Conforma Therapeutics Corp. Methods for treating genetically-defined proliferative disorders with hsp90 inhibitors
EP1387678A1 (en) 2001-05-03 2004-02-11 Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V. Compounds that inhibit hsp90 and stimulate hsp70 and hsp40, useful in the prevention or treatment of diseases associated with protein aggregation and amyloid formation
JP2004529188A (ja) 2001-05-23 2004-09-24 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ 上昇に関連した癌の治療法
JP4102124B2 (ja) 2001-08-01 2008-06-18 富士フイルム株式会社 ハロゲン化銀乳剤およびハロゲン化銀写真感光材料
WO2003013430A2 (en) 2001-08-06 2003-02-20 Kosan Biosciences, Inc. Benzoquinone ansamycins
BR0214553A (pt) * 2001-11-28 2004-10-13 Sod Conseils Rech Applic Compostos, processo de preparação, em fase lìquida, dos compostos, e, composições farmacêuticas
US20050074457A1 (en) 2001-12-12 2005-04-07 Adeela Kamal Assays and implements for determining and modulating hsp90 binding activity
EP1456180B1 (en) 2001-12-21 2007-10-03 Vernalis (Cambridge) Limited 3-(2,4)dihydroxyphenyl-4-phenylpyrazoles and their medical use
GB0207362D0 (en) 2002-03-28 2002-05-08 Univ Liverpool Chemotherapy
AU2003277299B2 (en) 2002-04-10 2009-12-10 Conforma Therapeutics Corporation Drug formulations having long and medium chain triglycerides
GB0208516D0 (en) 2002-04-15 2002-05-22 Univ Liverpool Chemotherapy
GB0228417D0 (en) 2002-12-05 2003-01-08 Cancer Rec Tech Ltd Pyrazole compounds
GB0229618D0 (en) 2002-12-19 2003-01-22 Cancer Rec Tech Ltd Pyrazole compounds
EA009919B1 (ru) 2003-02-11 2008-04-28 Вернэлис (Кембридж) Лимитед Соединения изоксазола
EP1457499A1 (en) 2003-03-12 2004-09-15 Tufts University School Of Medicine Inhibitors of extracellular Hsp90
WO2004089367A1 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S Pharmaceutical use of substituted 1,2,4-triazoles
JP2006522750A (ja) 2003-04-11 2006-10-05 ノボ　ノルディスク　アクティーゼルスカブ 代謝性症候群ならびに関連の疾患および障害を治療するために、１１β−ヒドロキシステロイドデヒドロゲナーゼ１型阻害剤および抗高血圧剤を使用する併用療法
EP1615667A2 (en) 2003-04-11 2006-01-18 Novo Nordisk A/S Combinations of an 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist
US20050054589A1 (en) 2003-05-30 2005-03-10 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with antibiotics
US20050020534A1 (en) 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with antimetabolites
US20050054625A1 (en) 2003-05-30 2005-03-10 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with nuclear export inhibitors
US7691838B2 (en) 2003-05-30 2010-04-06 Kosan Biosciences Incorporated Method for treating diseases using HSP90-inhibiting agents in combination with antimitotics
US20050020556A1 (en) 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with platinum coordination complexes
US20050020557A1 (en) 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with enzyme inhibitors
US20050026893A1 (en) 2003-05-30 2005-02-03 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with immunosuppressants
GB0315111D0 (en) 2003-06-27 2003-07-30 Cancer Rec Tech Ltd Substituted 5-membered ring compounds and their use
CA2532026C (en) 2003-08-20 2012-04-17 Eli Lilly And Company Compounds, methods and formulations for the oral delivery of a glucagon like peptide (glp)-1 compound or an melanocortin 4 receptor (mc4) agonist peptide
JP2005084612A (ja) * 2003-09-11 2005-03-31 Fuji Photo Film Co Ltd ハロゲン化銀乳剤、ハロゲン化銀感光材料、および熱現像感光材料
CA2542682A1 (en) * 2003-10-18 2005-05-06 Bayer Healthcare Ag 5-substituted 2-(phenylmethyl) thio-4-phenyl-4h-1,2,4-triazole derivatives and related compounds as gaba-agonists for the treatment of urinary incontinence and related diseases
WO2005082866A2 (en) 2004-02-20 2005-09-09 Pfizer Limited Substituted 1, 2, 4- triazole derivatives as oxytocin antagonists
WO2005097758A1 (en) * 2004-03-26 2005-10-20 Amphora Discovery Corporation Certain triazole-based compounds, compositions, and uses thereof
US20060235034A1 (en) 2004-11-01 2006-10-19 Nouri Neamati Novel compounds for treatment of cancer and disorders associated with angiogenesis function
WO2006055760A1 (en) 2004-11-18 2006-05-26 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
DE102005007304A1 (de) * 2005-02-17 2006-08-24 Merck Patent Gmbh Triazolderivate
RU2007137133A (ru) 2005-03-09 2009-04-20 Ниппон Каяку Кабусики Кайся (Jp) Новый ингибитор hsp90
US7473784B2 (en) 2005-08-01 2009-01-06 Bristol-Myers Squibb Company Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors
JP5178515B2 (ja) 2005-08-12 2013-04-10 シンタ ファーマシューティカルズ コーポレーション Ｈｓｐ９０活性を調節するピラゾール化合物
WO2007094819A2 (en) 2005-08-18 2007-08-23 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
EP1951679B1 (en) 2005-08-18 2015-02-18 Synta Pharmaceuticals Corp. Imidazole compounds that modulate hsp90 activity
DE102006023337A1 (de) 2006-05-18 2007-11-22 Merck Patent Gmbh Triazolderivate II
EP2026797A2 (en) 2006-05-25 2009-02-25 Synta Pharmaceuticals Corporation Method for treating non-hodgkin's lymphoma
AU2007267843B2 (en) 2006-05-25 2011-10-13 Synta Pharmaceuticals Corp. Method for treating proliferative disorders associated with protooncogene products
TW200806637A (en) 2006-05-25 2008-02-01 Synta Pharmaceuticals Corp Synthesis of triazole compounds that modulate HSP90 activity
US8183384B2 (en) 2006-05-25 2012-05-22 Synta Pharmaceuticals Corp. Triazole compounds that modulate HSP90 activity
WO2007139960A2 (en) 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Compounds that modulate hsp90 activity and methods for identifying same
CA2653222A1 (en) 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
EP2035396B1 (en) 2006-05-25 2014-05-14 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
WO2008021364A2 (en) 2006-08-17 2008-02-21 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
ES2584840T3 (es) 2006-10-03 2016-09-29 Nippon Kayaku Kabushiki Kaisha Compuesto de un derivado de resorcinol con un polímero
US20110046125A1 (en) 2006-10-19 2011-02-24 Synta Pharmaceuticals Corp. Method for treating infections
WO2008057246A2 (en) 2006-10-26 2008-05-15 Synta Pharmaceuticals Corp. Method for treating inflammatory disorders

Similar Documents

Publication Publication Date Title
JP2009504772A5 (https=)
JP2009505988A5 (https=)
JP2009504669A5 (https=)
JP2015522650A5 (https=)
JP2021524838A5 (https=)
JP2016516043A5 (https=)
JP2010518128A5 (https=)
EA027280B1 (ru) Сульфамоил-ариламиды и их применение в качестве лекарственных препаратов для лечения гепатита b
JP2014528467A5 (https=)
JP2020502049A5 (https=)
RU2018127728A (ru) Слитые трициклические гетероциклические соединения в качестве ингибиторов интегразы вич
JP2017531041A5 (https=)
JP2017528467A5 (https=)
JP2016513696A5 (https=)
EP4458348A3 (en) Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof
JP2017523169A5 (https=)
JP2012519691A5 (https=)
JP2005526857A5 (https=)
JP2011526917A5 (https=)
JP2013508378A5 (https=)
JP2011513305A5 (https=)
RU2012108629A (ru) Фенилэтинильные производные в качестве ингибиторов вируса гепатита с
RU2007116119A (ru) Производные циклоспорина, замещенные 3-эфиром и 3-тиоэфиром, для лечения и профилактики инфекционного гепатита с
JP2016531121A5 (https=)
NZ593712A (en) Intermediates for synthesising nucleoside aryl phosphoramidates